Siddiqui Mustaqeem, Ristow Kay, Markovic Svetomir N, Witzig Thomas E, Habermann Thomas M, Colgan Joseph P, Inwards David J, White William L, Ansell Stephen M, Micallef Ivana N, Johnston Patrick B, Call Timothy G, Porrata Luis F
Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.
Br J Haematol. 2006 Sep;134(6):596-601. doi: 10.1111/j.1365-2141.2006.06232.x. Epub 2006 Aug 1.
The peripheral blood absolute lymphocyte count (ALC) recovery after autologous stem cell transplantation has been shown to be an independent prognostic factor for survival for different haematologic malignancies. The role of ALC at diagnosis for follicular (grades 1 and 2) lymphomas (FL) on survival is not well described. The primary objective of this study was to assess the role of ALC on overall survival (OS) in FL patients. Of 1104 FL patients, 228 patients were originally diagnosed, followed, and had all treatment at the Mayo Clinic from 1984 and 1999, were evaluated. The median follow-up was 89 months (range: 8.35-248). ALC as a continuous variable was identified as a predictor for OS [Hazard ratio (HR) = 0.74, P < 0.04]. ALC >/= 1.0 x 10(9)/l (n = 164) predicted a longer OS versus ALC < 1.0 x 10(9)/l (n = 64; 175 vs. 73 months respectively, P < 0.0001). When compared with the Follicular Lymphoma International Prognostic Index (FLIPI), ALC was an independent prognostic factor for OS by multivariate analysis (HR = 0.677, P < 0.0001). These data suggest a critical role of FL patients' immune status at diagnosis on survival.
自体干细胞移植后外周血绝对淋巴细胞计数(ALC)的恢复已被证明是不同血液系统恶性肿瘤生存的独立预后因素。关于滤泡性(1级和2级)淋巴瘤(FL)诊断时ALC对生存的作用描述尚不充分。本研究的主要目的是评估ALC在FL患者总生存(OS)中的作用。对1104例FL患者中的228例进行了评估,这些患者于1984年至1999年在梅奥诊所首次诊断、接受随访并接受了所有治疗。中位随访时间为89个月(范围:8.35 - 248个月)。ALC作为连续变量被确定为OS的预测因素[风险比(HR)= 0.74,P < 0.04]。ALC≥1.0×10⁹/L(n = 164)的患者与ALC < 1.0×10⁹/L(n = 64)的患者相比,OS更长(分别为175个月和73个月,P < 0.0001)。与滤泡性淋巴瘤国际预后指数(FLIPI)相比,多因素分析显示ALC是OS的独立预后因素(HR = 0.677,P < 0.0001)。这些数据表明FL患者诊断时的免疫状态对生存起着关键作用。